SWISS-BASED PHARMA COMPANY IN EURO 400 MILLION CHINA INVESTMENT DEAL
November 3rd, 2013
A SWITZERLAND and Greece-based pharmaceutical company Sellas Life Sciences has signed a Euro EUR388 million investment deal with China’s Fochon Pharma for developing and selling two novel molecules for treating type II diabetes and lung cancer. Under the deal, Sellas will acquire the worldwide rights, outside China, to sell the resulting medicines, having organised and funded the clinical trials, some in Greece. Fochon, which discovered the molecules, will keep China sales rights and a 10% sales royalty. A Sellas communiqué said: “It is estimated that if the ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.